Birchview Capital’s Nektar Therapeutics NKTR Stock Holding History

Birchview Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.23M	Hold	31,000	–	–	1.27%	19
2025 Q4	$1.31M	Buy	31,000 +26,979	+671%	+$1.51M	0.77%	34
2025 Q3	$229K	Buy	+4,021	New	+$133K	0.17%	62
2023 Q4	–	Sell	-1,867	Closed	-$16.7K	–	59
2023 Q3	$16.7K	Hold	1,867	–	–	0.01%	50
2023 Q2	$16.1K	Sell	1,867 -6,000	-76%	-$64K	0.01%	54
2023 Q1	$83K	Hold	7,867	–	–	0.07%	52
2022 Q4	$267K	Sell	7,867 -666	-8%	-$32.2K	0.19%	45
2022 Q3	$410K	Hold	8,533	–	–	0.29%	41
2022 Q2	$486K	Hold	8,533	–	–	0.35%	38
2022 Q1	$690K	Buy	8,533 +1,866	+28%	+$276K	0.5%	35
2021 Q4	$1.35M	Buy	6,667 +1,867	+39%	+$405K	0.87%	22
2021 Q3	$1.29M	Hold	4,800	–	–	0.88%	24
2021 Q2	$1.24M	Sell	4,800 -1,333	-22%	-$369K	0.74%	23
2021 Q1	$1.84M	Buy	+6,133	New	+$1.91M	1.09%	16
2019 Q3	–	Sell	-633	Closed	-$338K	–	54
2019 Q2	$338K	Hold	633	–	–	0.21%	38
2019 Q1	$319K	Hold	633	–	–	0.2%	41
2018 Q4	$312K	Hold	633	–	–	0.3%	35
2018 Q3	$579K	Hold	633	–	–	0.37%	29
2018 Q2	$464K	Buy	+633	New	+$730K	0.32%	32

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Birchview Capital's NKTR Position: Q1 2026 in Review

Birchview Capital held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 31,000 shares worth $2.23M. The position accounts for 1.27% of the portfolio, ranked #19.

Birchview Capital first reported a position in NKTR in Q2 2018 and has held it in 19 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Birchview Capital held 31,000 shares of Nektar Therapeutics worth $2.23M as of Q1 2026.
Birchview Capital left its Nektar Therapeutics share count unchanged in Q1 2026.
Nektar Therapeutics made up 1.27% of Birchview Capital's portfolio in Q1 2026, its #19 holding.
Birchview Capital first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 19 quarters since.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.